Research programme: erythropoietin long-acting - Bolder BioTechnology

Drug Profile

Research programme: erythropoietin long-acting - Bolder BioTechnology

Alternative Names: BBT-009; BBT-021

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bolder BioTechnology
  • Class Antianaemics; Erythropoietins; Polyethylene glycols
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anaemia

Most Recent Events

  • 04 Dec 2017 Erythropoietin long-acting is still in preclinical development for anaemia in USA (Bolder Biotechnology pipeline, November 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia in USA (Parenteral)
  • 05 Nov 2010 Bolder BioTechnology receives a Qualifying Therapeutic Discovery Project grant from the US Department of Health and Human Services for BBT 021 development in Anaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top